Status:
UNKNOWN
Qingre Huashi Granules Combined the Modified Dual Therapy for Helicobacter Pylori Infection
Lead Sponsor:
Peking University First Hospital
Collaborating Sponsors:
Peking University International Hospital
Beijing Geriatric Hospital
Conditions:
Helicobacter Pylori Infection
Eligibility:
All Genders
60+ years
Phase:
NA
Brief Summary
This is an open-label, randomized controlled trial. The aim of the study is to evaluate the efficacy and safety of the Qingre Huashi Granules combined the modified dual therapy (or called high dose du...
Eligibility Criteria
Inclusion
- Current Helicobacter pylori infection.
- Age ≥ 60 years.
- Diagnosed with syndrome of dampness-heat by Traditional Chinese Medicine.
- Signed the informed consent document.
Exclusion
- History of Helicobacter pylori treatment.
- History of gastric surgery.
- Allergic to any medications involved in the intervention.
- Sever complications, such as lung dysfunction, uncontrolled hypertension, diabetes, cardiovascular disease, renal dysfunction (eGFR\<60ml/min'1.73m2) , malignant tumor，mental disorder.
- Taking medications that may be conflict to the intervention drugs.
- Failing to express symptoms, unwilling to cooperate.
- Taking any antibiotics within a month.
Key Trial Info
Start Date :
August 5 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT05364619
Start Date
August 5 2022
End Date
December 31 2024
Last Update
October 18 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034
2
Beijing Changping Integrative Medicine Hospital
Beijing, Beijing Municipality, China
3
Peking University International Hospital
Beijing, Beijing Municipality, China